Inhibin-alpha,-betaA and-betaB subunits in uterine non-endometrioid carcinomas: Prognostic significance and clinical implications

European Journal of Cancer

Volumn 46, Issue 13, 2010, Pages 2485-2493

  Mylonas, Ioannis ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Endometrial cancer; Immunohistochemistry; Inhibin subunits; Non endometrioid carcinomas; Prognosis; Survival

Indexed keywords

INHIBIN; INHIBIN ALPHA; INHIBIN BETAA; INHIBIN BETAB; MONOCLONAL ANTIBODY; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIOID CARCINOMA; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UTERUS CARCINOMA;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBIN-BETA SUBUNITS; INHIBINS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; UTERINE NEOPLASMS;

EID: 77955920912     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.06.001     Document Type: Article

References (49)

1. F. Amant, P. Moerman, and P. Neven Endometrial cancer Lancet 366 9484 2005 491 505
2. J. Prat Prognostic parameters of endometrial carcinoma Hum Pathol 35 6 2004 649 662
3. B. Jereczek-Fossa, A. Badzio, and J. Jassem Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure Int J Gynecol Cancer 9 4 1999 285 294
4. L.A. Gloeckler Ries, M.E. Reichman, D.R. Lewis, B.F. Hankey, and B.K. Edwards Cancer survival and incidence from the surveillance, epidemiology, and end results (SEER) program Oncologist 8 6 2003 541 552
5. L. Deligdisch, and C.F. Holinka Endometrial carcinoma: two diseases? Cancer Detect Prev 10 3-4 1987 237 246
6. J.V. Bokhman Two pathogenetic types of endometrial carcinoma Gynecol Oncol 15 1 1983 10 17
7. S.F. Lax Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification Virchows Arch 444 3 2004 213 223
8. D. Faratian, A. Stillie, R.M. Busby-Earle, V.J. Cowie, and H. Monaghan A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome Int J Gynecol Cancer 16 3 2006 972 978
9. N. Macwhinnie, and H. Monaghan The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma Int J Gynecol Cancer 14 5 2004 938 946
10. J.A. Villella, S. Cohen, D.H. Smith, H. Hibshoosh, and D. Hershman HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications Int J Gynecol Cancer 16 5 2006 1897 1902
11. W. Vale, E. Wiater, and P. Gray Activins and inhibins and their signaling Ann NY Acad Sci 1038 2004 142 147
12. W. Vale, C. Rivier, and A. Hsueh Chemical and biological characterization of the inhibin family of protein hormones Recent Prog Horm Res 44 1988 1 34
13. Y. Xia, and A.L. Schneyer The biology of activin: recent advances in structure, regulation and function J Endocrinol 202 1 2009 1 12
14. G.P. Risbridger, J.F. Schmitt, and D.M. Robertson Activins and inhibins in endocrine and other tumors Endocr Rev 22 6 2001 836 858
15. F. Petraglia, P. Florio, and S. Luisi Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma J Clin Endocrinol Metab 83 4 1998 1194 1200
16. S. Worbs, N. Shabani, and D. Mayr Expression of the inhibin/activin subunits (-alpha,-betaA and-betaB) in normal and carcinogenic endometrial tissue: possible immunohistochemical differentiation markers Oncol Rep 17 1 2007 97 104
17. I. Mylonas, S. Worbs, and N. Shabani Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha,-betaA and-betaB subunits in 302 cases Eur J Cancer 45 7 2009 1304 1314
18. G.P. Risbridger, E.M. Ball, H. Wang, S.L. Mellor, and D.M. Peehl Re-evaluation of inhibin alpha subunit as a tumour suppressor in prostate cancer Mol Cell Endocrinol 225 1-2 2004 73 76
19. M.M. Matzuk, M.J. Finegold, J.G. Su, A.J. Hsueh, and A. Bradley Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice Nature 360 6402 1992 313 319
20. M.M. Matzuk, M.J. Finegold, and J.P. Mather Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice Proc Natl Acad Sci USA 91 19 1994 8817 8821
21. P. Florio, P. Ciarmela, and F.M. Reis Inhibin alpha-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma Eur J Endocrinol 152 2 2005 277 284
22. I. Mylonas, J. Makovitzky, and D.U. Richter Expression of the inhibin-alpha subunit in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis Gynecol Oncol 93 1 2004 92 97
23. N. Shabani, C. Kuhn, and S. Kunze Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas Eur J Cancer 43 16 2007 2434 2444
24. P.B. Clement, and R.H. Young Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects Adv Anat Pathol 11 3 2004 117 142
25. FIGO stages Announcements Gynecol Oncol 35 1989 125 127
26. I. Mylonas, U. Jeschke, and I. Wiest Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle Histochem Cell Biol 122 5 2004 461 471
27. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
28. D.R. Cox Regression models and life tables J R Stat Soc B 34 1972 187 220
29. S. Ehata, A. Hanyu, and M. Fujime Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line Cancer Sci 98 1 2007 127 133
30. H. Ogino, S. Yano, and S. Kakiuchi Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice Clin Cancer Res 14 3 2008 660 667
31. K. Tsuchida, M. Nakatani, and K. Hitachi Cell Commun Signal 7 2009 15
32. J.S. Jeruss, C.D. Sturgis, A.W. Rademaker, and T.K. Woodruff Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer Cancer Res 63 13 2003 3783 3790
33. H.B. Adkins, C. Bianco, and S.G. Schiffer Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo J Clin Invest 112 4 2003 575 587
34. D. Razanajaona, S. Joguet, and A.S. Ay Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth Cancer Res 67 15 2007 7223 7229
35. J.E. Burdette, and T.K. Woodruff Activin and estrogen crosstalk regulates transcription in human breast cancer cells Endocr Relat Cancer 14 3 2007 679 689
36. A. Ramachandran, E.S. Marshall, D.R. Love, B.C. Baguley, and A.N. Shelling Activin is a potent growth suppressor of epithelial ovarian cancer cells Cancer Lett 2009
37. I. Katik, C. Mackenzie-Kludas, and C. Nicholls Biochem Biophys Res Commun 2009
38. N. Di Simone, H.A. Hall, C. Welt, and A.L. Schneyer Activin regulates betaA-subunit and activin receptor messenger ribonucleic acid and cellular proliferation in activin-responsive testicular tumor cells Endocrinology 139 3 1998 1147 1155
39. N. Di Simone, A.L. Schneyer, D. Caliandro, R. Castellani, and A. Caruso Regulation of endometrial adenocarcinoma cell proliferation by activin-A and its modulation by 17beta-estradiol Mol Cell Endocrinol 192 1-2 2002 187 195
40. N. Sharifi, R.J. Lechleider, and W.L. Farrar Transforming growth factor-beta receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate? J Mol Endocrinol 39 5 2007 329 332
41. D.J. Phillips, D.M. de Kretser, and M.P. Hedger Activin and related proteins in inflammation: not just interested bystanders Cytokine Growth Factor Rev 20 2 2009 153 164
42. S.A. McCarthy, and R. Bicknell Inhibition of vascular endothelial cell growth by activin-A J Biol Chem 268 31 1993 23066 23071
43. C.W. Seder, W. Hartojo, and L. Lin Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma Neoplasia 11 4 2009 388 396
44. C.W. Brown, D.E. Houston-Hawkins, T.K. Woodruff, and M.M. Matzuk Insertion of Inhbb into the Inhba locus rescues the Inhba-null phenotype and reveals new activin functions Nat Genet 25 4 2000 453 457
45. T.B. Thompson, R.W. Cook, S.C. Chapman, T.S. Jardetzky, and T.K. Woodruff Beta A versus beta B: is it merely a matter of expression? Mol Cell Endocrinol 225 1-2 2004 9 17
46. Y. Makanji, P.D. Temple-Smith, K.L. Walton, C.A. Harrison, and D.M. Robertson Inhibin B is a more potent suppressor of rat follicle-stimulating hormone release than inhibin a in vitro and in vivo Endocrinology 150 10 2009 4784 4793
47. P.G. Farnworth, P.G. Stanton, and Y. Wang Inhibins differentially antagonize activin and bone morphogenetic protein action in a mouse adrenocortical cell line Endocrinology 147 7 2006 3462 3471
48. K.K. Vihko, M. Blauer, U. Puistola, and P. Tuohimaa Activin B in patients with granulosa cell tumors: serum levels in comparison to inhibin Acta Obstet Gynecol Scand 82 6 2003 570 574
49. F. Petraglia, S. Luisi, and P. Pautier Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors J Clin Endocrinol Metab 83 3 1998 1029 1032